Surface Therapeutics Ltd.

Surface Therapeutics Ltd. is a biotechnology firm focused on developing innovative therapeutic solutions aimed at enhancing treatment outcomes for various health conditions. Surface Therapeutics Ltd. is a biotechnology company that specializes in therapeutic solutions.

In October 2007, the company was acquired by Serentis Inc. , which is backed by investment firms Apposite Capital, MVM Life Science Partners, and Novo A/S. The firm is headquartered in Abingdon, UK. Surface Therapeutics Ltd.

specializes in a range of innovative therapeutic products aimed at improving health outcomes across various medical sectors. Their core offerings include advanced drug formulations and delivery systems designed to enhance treatment effectiveness and patient compliance. The company focuses on therapeutic areas such as oncology and chronic diseases, with a commitment to addressing unmet medical needs. Their solutions are utilized by healthcare providers and research institutions globally, encompassing a client base in North America, Europe, and Asia.

The company generates revenue through partnerships with healthcare providers and pharmaceutical companies, focusing on licensing agreements and collaborative research initiatives. Revenue streams are bolstered by the sale of proprietary therapeutic products and royalties from successful drug commercialization efforts. By maintaining strategic alliances, Surface Therapeutics Ltd. ensures a steady flow of income while fostering innovation in treatment modalities.

Surface Therapeutics Ltd. is focused on expanding its product line with new therapeutic offerings aimed at launching within the next two years. The company plans to enter new markets, particularly targeting regions in Asia and Europe by 2025. The funding acquired in October 2007 from the acquisition by Serentis Inc.

is expected to support these initiatives by enhancing research and development capabilities, ensuring the company remains at the forefront of therapeutic advancements.